Showing results (1-10 of 1,146) with videos related to

Sort By:
Pageof 115
Schizophrenia Research|January 12, 2010
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 studyMarc De Hert, Christoph U Correll, Dan Cohen
European Child & Adolescent Psychiatry|February 8, 2011
Prevalence and correlates of seclusion and restraint use in children and adolescents: a systematic reviewMarc De Hert, Nele Dirix, Hella Demunter, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 5, 2015
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorderChristoph U Correll, Johan Detraux, Jan De Lepeleire, et al.
The Journal of Clinical Psychiatry|June 24, 2016
Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled TrialsChristoph U Correll, Lawrence Maayan, John Kane, et al.
Nature Reviews. Endocrinology|October 20, 2011
Metabolic and cardiovascular adverse effects associated with antipsychotic drugsMarc De Hert, Johan Detraux, Ruud van Winkel, et al.
The Journal of Clinical Psychiatry|January 10, 2012
Prediabetes in patients treated with antipsychotic drugsPeter Manu, Christoph U Correll, Ruud van Winkel, et al.
Current Opinion in Psychiatry|June 30, 2012
Osteoporosis and fracture risk in people with schizophreniaTaishiro Kishimoto, Marc De Hert, Harold E Carlson, et al.
Expert Opinion on Drug Safety|May 9, 2012
Safety and tolerability of antipsychotic polypharmacyJuan A Gallego, Jimmi Nielsen, Marc De Hert, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 6, 2013
Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventionsGabriel Gerlinger, Marta Hauser, Marc De Hert, et al.
CNS Drugs|August 21, 2012
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysisMarc De Hert, Weiping Yu, Johan Detraux, et al.
Pageof 115